Literature DB >> 9102216

Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice.

K Smith-McCune1, Y H Zhu, D Hanahan, J Arbeit.   

Abstract

Infection of the human cervix with certain papillomavirus subtypes is associated with the development of neoplastic squamous lesions that can progress to overt cervical malignancies. Recently, multistage squamous carcinogenesis has been achieved in K14-HPV16 transgenic mice, wherein expression of the human papillomavirus (HPV) type 16 early genes is targeted to basal squamous epithelial cells by regulatory elements of the human keratin-14 (K14) promoter. Immunostaining of the endothelial marker vWf revealed a parallel upregulation of angiogenesis during the early neoplastic stages in both human cervix and the epidermis of K14-HPV16 transgenic mice. Moreover, high-grade premalignant lesions and cancers in humans and transgenic mice were characterized by an additional increment in the number of new capillaries and close apposition of the microvasculature to the overlying neoplastic epithelium. Expression of the potent angiogenic factor VEGF was progressively up-regulated during carcinogenesis in both species, correlating with the increased density and altered distribution of the microvasculature. Thus, angiogenesis occurs during the premalignant stages of squamous carcinogenesis in both human cervical disease and a relevant transgenic model and may be controlled by similar molecular mechanisms in both species. These results validate the use of the transgenic model to elucidate the role of angiogenesis during HPV-associated neoplastic progression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9102216

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Immunohistochemical analysis, human papillomavirus DNA detection, hormonal manipulation, and exogenous gene expression of normal and dysplastic human cervical epithelium in severe combined immunodeficiency mice.

Authors:  J A Taylor; K Tewari; S Y Liao; C C Hughes; L P Villarreal
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer.

Authors:  M Branca; C Giorgi; D Santini; L Di Bonito; M Ciotti; A Benedetto; P Paba; S Costa; D Bonifacio; P Di Bonito; L Accardi; C Favalli; K Syrjänen
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

3.  Expression profile of microRNA-146a along HPV-induced multistep carcinogenesis: a study in HPV16 transgenic mice.

Authors:  Rita Araújo; Joana M O Santos; Mara Fernandes; Francisca Dias; Hugo Sousa; Joana Ribeiro; Margarida M S M Bastos; Paula A Oliveira; Diogo Carmo; Fátima Casaca; Sandra Silva; Rui Medeiros; Rui M Gil da Costa
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-27       Impact factor: 4.553

Review 4.  Persistence of human papillomavirus infection: keys to malignant progression.

Authors:  Jason Bodily; Laimonis A Laimins
Journal:  Trends Microbiol       Date:  2010-11-01       Impact factor: 17.079

5.  The expression and underlying angiogenesis effect of DPC4 and VEGF on the progression of cervical carcinoma.

Authors:  Yanni A; Ying Li; Shuping Zhao
Journal:  Oncol Lett       Date:  2017-12-11       Impact factor: 2.967

6.  A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Janet S Rader; Michael W Sill; Jan H Beumer; Heather A Lankes; Doris Mangiaracina Benbrook; Francisco Garcia; Connie Trimble; J Tate Thigpen; Richard Lieberman; Rosemary E Zuna; Charles A Leath; Nick M Spirtos; John Byron; Premal H Thaker; Shashikant Lele; David Alberts
Journal:  Gynecol Oncol       Date:  2017-03-10       Impact factor: 5.482

7.  A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  John K Chan; Wei Deng; Robert V Higgins; Krishnansu S Tewari; Albert J Bonebrake; Michael Hicks; Stephanie Gaillard; Pedro T Ramirez; Weldon Chafe; Bradley J Monk; Carol Aghajanian
Journal:  Gynecol Oncol       Date:  2017-07-18       Impact factor: 5.482

8.  Detection of targeted perfluorocarbon nanoparticle binding using 19F diffusion weighted MR spectroscopy.

Authors:  Emily A Waters; Junjie Chen; Xiaoxia Yang; Huiying Zhang; Robert Neumann; Andrea Santeford; Jeffrey Arbeit; Gregory M Lanza; Samuel A Wickline
Journal:  Magn Reson Med       Date:  2008-11       Impact factor: 4.668

9.  Magnetic resonance imaging defines cervicovaginal anatomy, cancer, and VEGF trap antiangiogenic efficacy in estrogen-treated K14-HPV16 transgenic mice.

Authors:  Joel R Garbow; Andrea C Santeford; Jeff R Anderson; John A Engelbach; Jeffrey M Arbeit
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

10.  An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.

Authors:  Enrico Giraudo; Masahiro Inoue; Douglas Hanahan
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.